Conclusion: Rhegmatogenous retinal detachment repair causes ocular changes, with significantly more decrease in corneal endothelial cell density after pars plana vitrectomy, and more increase in anterior chamber
depth and axial length after scleral buckling.
There should be minimal or no limbal hyperaemia and no visible anterior chamber
His anterior chamber
was filled with viscoelastic substance and the lens was brought into position and re-enclaved.
Paracentesis of the anterior chamber
was performed at a slit lamp with a sterile 30-gauge needle while the clinician was wearing personal protective equipment.
Pupil diameter (PD), anterior chamber
depth (ACD), anterior chamber
angle (ACA), angle opening distances (AOD) at both 500 [micro]m and 250 [micro]m (AOD250) were measured from the UBM scans and evaluated to determine whether any significant changes occurred in the AS in the drug-free period.
Statistically significant differences favoring KPI-121 1% administered twice-a-day versus placebo were achieved for both primary endpoints, the proportion of patients with complete resolution of anterior chamber
cells at day 8 (p=0.
In our study, only one eye had a flat anterior chamber
and hypotonia secondary to suprachoroid hemorrhage.
is moderately deep, the iris and iris root are comparatively thick and the iris surface is planar.
maintainer was used during entire procedure and use of viscoelastic material was avoided.
of eye affections such as hyphema and hypopyon were recorded in 2 and 3 animals respectively.
The mice were subsequently divided randomly into three control groups and one study group: normal control group (Group A, n = 6) without any treatment; CA control group (Group B, n = 6) with feeding the CA solution; microbeads (MBs) control group (Group C, n = 6) with injecting MB into the anterior chamber
to induce chronic elevation of IOP; CA study group (Group D, n = 6) with injecting MB into the anterior chamber
and with feeding the CA solution as well.
The research collaboration also provides Aerie with the ability to evaluate long-term sustained delivery of the active ingredient in Rhopressa to the anterior chamber
of the eye for patients with glaucoma and ocular hypertension.